Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study.

@article{Launay2008ImmunologicalEO,
  title={Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study.},
  author={Odile Launay and Sophie Grabar and Emmanuel Gordien and Corinne Desaint and David J{\'e}gou and S{\'e}bastien Abad and P O Girard and Linda B{\'e}larbi and Corinne Gu{\'e}rin and J{\'e}r{\^o}me Dimet and Virginie Williams and Anne Krivine and D Salmon and Olivier Lortholary and David Rey},
  journal={Journal of acquired immune deficiency syndromes},
  year={2008},
  volume={49 3},
  pages={272-5}
}
BACKGROUND The immunogenicity of vaccines, including vaccine against hepatitis A virus (HAV), is impaired in patients with HIV infection, requiring revised immunization regimens. METHODS We evaluated the immunological efficacy and safety of a 3-dose schedule of hepatitis A vaccine in HIV-infected adults. HAV-seronegative HIV-infected adults were randomized to receive either 3 doses of 1440 UI of hepatitis A vaccine (HAVRIX; GlaxoSmithKline, Marly le Roi, France) at weeks 0, 4, and 24 (46… CONTINUE READING
18 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

Similar Papers

Loading similar papers…